(R)-1-(6-(2H-tetrazol-5-yl)hexyl)-5-((R,E)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl)pyrrolidin-2-one

ID: ALA1956373

Cas Number: 634193-54-7

PubChem CID: 11316084

Product Number: L611430, Order Now?

Max Phase: Preclinical

Molecular Formula: C21H27F2N5O2

Molecular Weight: 419.48

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C1CC[C@H](/C=C/[C@@H](O)C(F)(F)c2ccccc2)N1CCCCCCc1nn[nH]n1

Standard InChI:  InChI=1S/C21H27F2N5O2/c22-21(23,16-8-4-3-5-9-16)18(29)13-11-17-12-14-20(30)28(17)15-7-2-1-6-10-19-24-26-27-25-19/h3-5,8-9,11,13,17-18,29H,1-2,6-7,10,12,14-15H2,(H,24,25,26,27)/b13-11+/t17-,18+/m0/s1

Standard InChI Key:  WPTLQOYLIXWRNN-SLKVGHROSA-N

Molfile:  

     RDKit          2D

 30 32  0  0  0  0  0  0  0  0999 V2000
   11.3333    0.4458    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.7500   -0.2708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1623    0.4483    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.9333    0.5458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.6478    0.9583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1567    0.8373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6423    0.1923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0968   -0.4963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8923   -0.2766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9372    1.6326    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.6074   -0.6880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3212   -0.2743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0364   -0.6857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0377   -1.5107    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.4653   -0.6834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4652   -1.5094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1795   -1.9207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8943   -1.5070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8903   -0.6777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1754   -0.2702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6478    1.7833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3623    2.1958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0767    1.7833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7912    2.1958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5057    1.7833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2207    2.1964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0102    1.9707    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.4710    2.6550    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.9625    3.3048    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.1875    3.0218    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2 15  1  0
  7  8  1  0
 15 16  2  0
  8  9  1  0
 16 17  1  0
  9  4  1  0
 17 18  2  0
  4  6  1  0
 18 19  1  0
  6 10  2  0
 19 20  2  0
 20 15  1  0
  3  2  1  0
  5 21  1  0
  9 11  1  1
 21 22  1  0
 22 23  1  0
 11 12  2  0
 23 24  1  0
  2  1  1  0
 24 25  1  0
 12 13  1  0
 25 26  1  0
 26 27  2  0
 13  2  1  0
  4  5  1  0
 13 14  1  6
  6  7  1  0
 27 28  1  0
 28 29  1  0
 29 30  2  0
 30 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA1956373

   L902688

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 419.48

Molecular Weight (Monoisotopic): 419.2133

AlogP: 3.00

#Rotatable Bonds: 11

Polar Surface Area: 95.00

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 5.88

CX Basic pKa: ┄

CX LogP: 3.68

CX LogD: 2.44

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.43

Np Likeness Score: -0.46

References

1. Arns S, Gibe R, Moreau A, Monzur Morshed M, Young RN..  (2012)  Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.,  20  (6): [PMID:22341574] [10.1016/j.bmc.2012.01.024]

Source

Source(1):

• Scientific Literature